Adaptimmune Therapeutics (NASDAQ: ADAP) reported Q2 EPS of ($0.02), $0.16 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $5.13 million versus the consensus estimate of $9.25 million.

For earnings history and earnings-related data on Adaptimmune Therapeutics (ADAP) click here.